TY - JOUR
T1 - Pathogenic variants in cancer predisposition genes and prostate cancer risk in men of african ancestry
AU - Matejcic, Marco
AU - Patel, Yesha
AU - Lilyquist, Jenna
AU - Hu, Chunling
AU - Lee, Kun Y.
AU - Gnanaolivu, Rohan D.
AU - Hart, Steven N.
AU - Polley, Eric C.
AU - Yadav, Siddhartha
AU - Boddicker, Nicholas J.
AU - Samara, Raed
AU - Xia, Lucy
AU - Sheng, Xin
AU - Lubmawa, Alexander
AU - Kiddu, Vicky
AU - Masaba, Benon
AU - Namuguzi, Dan
AU - Mutema, George
AU - Job, Kuteesa
AU - Dabanja, Henry M.
AU - Ingles, Sue A.
AU - Wilkens, Lynne
AU - Le Marchand, Loic
AU - Watya, Stephen
AU - Couch, Fergus J.
AU - Conti, David V.
AU - Haiman, Christopher A.
N1 - Funding Information:
Supported by the National Institutes of Health (Grant No. R01 CA 165862) and the California Cancer Research Program (Grant No. 99-00524V-10258). The Multiethnic Cohort study was supported by Grant No. U01 CA164973.
Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2019
Y1 - 2019
N2 - PURPOSE In studies of men of European ancestry, rare pathogenic variants in DNA repair pathway genes have been shown to be associated with risk of aggressive prostate cancer. The contribution of rare coding variation to prostate cancer risk in men of African ancestry has not been established. METHODS We sequenced a panel of 19 DNA repair and cancer predisposition genes in 2,453 African American and 1,151 Ugandan cases and controls with prostate cancer. Rare variants were classified as pathogenic or putatively functionally disruptive and examined in association with prostate cancer risk and disease aggressiveness in gene and pathway-level association analyses. RESULTS Pathogenic variants were found in 75 of 2,098 cases (3.6%) and 31 of 1,481 controls (2.1%; odds ratio [OR], 1.82; 95% CI, 1.19 to 2.79; P = .0044), with the association being stronger for more aggressive disease phenotypes (OR, 3.10; 95% CI, 1.54 to 6.23; P = .0022). The highest risks for aggressive disease were observed with pathogenic variants in the ATM, BRCA2, PALB2, and NBN genes, with ORs ranging from approximately 4 to 15 in the combined study sample of African American and Ugandan men. Rare, nonpathogenic, nonsynonymous variants did not have a major impact on risk of overall prostate cancer or disease aggressiveness. CONCLUSION Rare pathogenic variants in DNA repair genes have appreciable effects on risk of aggressive prostate cancer in men of African ancestry. These findings have potential implications for panel testing and risk stratification in this high-risk population.
AB - PURPOSE In studies of men of European ancestry, rare pathogenic variants in DNA repair pathway genes have been shown to be associated with risk of aggressive prostate cancer. The contribution of rare coding variation to prostate cancer risk in men of African ancestry has not been established. METHODS We sequenced a panel of 19 DNA repair and cancer predisposition genes in 2,453 African American and 1,151 Ugandan cases and controls with prostate cancer. Rare variants were classified as pathogenic or putatively functionally disruptive and examined in association with prostate cancer risk and disease aggressiveness in gene and pathway-level association analyses. RESULTS Pathogenic variants were found in 75 of 2,098 cases (3.6%) and 31 of 1,481 controls (2.1%; odds ratio [OR], 1.82; 95% CI, 1.19 to 2.79; P = .0044), with the association being stronger for more aggressive disease phenotypes (OR, 3.10; 95% CI, 1.54 to 6.23; P = .0022). The highest risks for aggressive disease were observed with pathogenic variants in the ATM, BRCA2, PALB2, and NBN genes, with ORs ranging from approximately 4 to 15 in the combined study sample of African American and Ugandan men. Rare, nonpathogenic, nonsynonymous variants did not have a major impact on risk of overall prostate cancer or disease aggressiveness. CONCLUSION Rare pathogenic variants in DNA repair genes have appreciable effects on risk of aggressive prostate cancer in men of African ancestry. These findings have potential implications for panel testing and risk stratification in this high-risk population.
UR - http://www.scopus.com/inward/record.url?scp=85086409226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086409226&partnerID=8YFLogxK
U2 - 10.1200/PO.19.00179
DO - 10.1200/PO.19.00179
M3 - Article
AN - SCOPUS:85086409226
SN - 2473-4284
VL - 3
SP - 32
EP - 43
JO - JCO Precision Oncology
JF - JCO Precision Oncology
ER -